In today’s briefing:
- BGH Ups The Ante For Control Of Virtus
- Pre-IPO Yunkang Group – Lack of New Growth Point
- Top Picks for Growth Stocks – Feb 2022
- BGH’s Revised Higher Offer for Virtus
- Dividend HealthCare Stocks Screener – Jan 2022
BGH Ups The Ante For Control Of Virtus
- Fertility specialist Virtus Health (VRT AU) has received a revised non-binding takeover bid from BGH Capital of $7.65/share, less any dividends declared by Virtus. It had previously offered $7.10/share.
- BGH also said it would vote its 19.99% stake against CapVest Partners’ cash offer of $7.60/share.
- Back in CapVest’s court. A $0.05/share higher bid is unlikely to see the UK-based player fold its tent.
Pre-IPO Yunkang Group – Lack of New Growth Point
- Benefiting from the opportunities brought to the healthcare industry by the COVID-19 pandemic in 2020, Yunkang Group (YK HK) took a ride and ushered in a turning point in performance.
- As the pandemic stabilizes and gets gradually under control, the revenue generated from COVID-19 tests may significantly decrease, which means Yunkang may return to net loss again in the future.
- We currently haven’t seen any new growth point with high certainty. Therefore, we are conservative about Yunkang’s outlook.
Top Picks for Growth Stocks – Feb 2022
- The market has been quite volatile these past couple of months. Unfortunately, it seems like volatility will stay for some time.
- Growth oriented tech stocks got especially hammered. While it might be quite upsetting seeing those red numbers, it is actually a good time for the savvy investor to buy!
- InMode designs, develops, manufactures, and sells minimally invasive aesthetic medical products. Simply speaking, they make and sell robotics for plastic surgery.
BGH’s Revised Higher Offer for Virtus
- BGH’s revised scheme offer will pay $7.65 per Virtus Health (VRT AU) share, which is 0.7% and 2.0% higher than CapVest’s rival scheme (A$7.60) and off-market takeover offer (A$7.50), respectively.
- BGH (19.99% stake) will vote against the CapVest scheme and will not accept any takeover offer from CapVest. Consequently, CapVest’s best option is an improved off-market takeover bid.
- As CapVest’s offer is marginally below BGH’s revised offer, CapVest retains the potential to lob an improved offer, in our view.
Dividend HealthCare Stocks Screener – Jan 2022
- It’s a volatile market these days! The Omicron variant, interest rate hikes, supply chain disruption, and labor shortage are causing the market to fluctuate wildly
- Healthcare companies provide essential services regardless of economic conditions.
- The screener results were quite satisfactory. AbbVie, Amgen, and Merck. I like all of them!
Before it’s here, it’s on Smartkarma
